SAHA Enhances Synaptic Function and Plasticity In Vitro but Has Limited Brain Availability In Vivo and Does Not Impact Cognition

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Hanson, Jesse E ^a   La, Hank ^a   Plise, Emile ^a   Chen, Yung Hsiang ^a   Ding, Xiao ^a   Hanania, Taleen ^b   Sabath, Emily V ^b   Alexandrov, Vadim ^b   Brunner, Dani ^b,c   Leahy, Emer ^b   Steiner, Pascal ^a   Liu, Lichuan ^a   Scearce Levie, Kimberly ^a   Zhou, Qiang ^a  

^a GENENTECH INC   (United States)

^b PSYCHOGENICS INC   (United States)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN; VORINOSTAT;

ACUTE DRUG ADMINISTRATION; ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CHRONIC DRUG ADMINISTRATION; COGNITION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BRAIN LEVEL; DRUG DOSE COMPARISON; DRUG PENETRATION; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; LONG TERM DEPRESSION; LONG TERM POTENTIATION; MEMORY DISORDER; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PHENOTYPE; PRESYNAPTIC POTENTIAL; SYNAPTIC POTENTIAL;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; BEHAVIOR, ANIMAL; BRAIN; CA1 REGION, HIPPOCAMPAL; COGNITION; CONDITIONING (PSYCHOLOGY); EXCITATORY POSTSYNAPTIC POTENTIALS; FEAR; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INHIBITORY CONCENTRATION 50; ISOENZYMES; LONG-TERM POTENTIATION; MEMBRANES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONAL PLASTICITY; P-GLYCOPROTEIN; PHENOTYPE; RATS; RATS, SPRAGUE-DAWLEY; SYNAPSES;

EID: 84880839200     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069964     Document Type: Article

References (49)

1. Jenuwein T, Allis CD, (2001) Translating the histone code. Science 293: 1074-1080.
2. Strahl BD, Allis CD, (2000) The language of covalent histone modifications. Nature 403: 41-45.
3. Spange S, Wagner T, Heinzel T, Kramer OH, (2009) Acetylation of non-histone proteins modulates cellular signalling at multiple levels. Int J Biochem Cell Biol 41: 185-198.
4. Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, et al. (2005) Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. Exp Hematol 33: 53-61.
5. Duvic M, Vu J, (2007) Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat. Biologics 1: 377-392.
6. Duvic M, Vu J, (2007) Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 16: 1111-1120.
7. Martinez-Iglesias O, Ruiz-Llorente L, Sanchez-Martinez R, Garcia L, Zambrano A, et al. (2008) Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer. Clin Transl Oncol 10: 395-398.
8. Archin NM, Liberty AL, Kashuba AD, Choudhary SK, Kuruc JD, et al. (2012) Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 487: 482-485.
9. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, et al. (2009) Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 284: 6782-6789.
10. Ververis K, Karagiannis TC, (2011) Potential non-oncological applications of histone deacetylase inhibitors. Am J Transl Res 3: 454-467.
11. Graff J, Kim D, Dobbin MM, Tsai LH, (2011) Epigenetic regulation of gene expression in physiological and pathological brain processes. Physiol Rev 91: 603-649.
12. Graff J, Rei D, Guan JS, Wang WY, Seo J, et al. (2012) An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 483: 222-226.
13. Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, et al. (2009) HDAC2 negatively regulates memory formation and synaptic plasticity. Nature 459: 55-60.
14. Rivieccio MA, Brochier C, Willis DE, Walker BA, D'Annibale MA, et al. (2009) HDAC6 is a target for protection and regeneration following injury in the nervous system. Proc Natl Acad Sci U S A 106: 19599-19604.
15. Brunner D, Alexandrov V, Calderone B, Hanania T, Lowe D (2012) Behavior-Based Screening as an Approach to Polypharmacological Ligands. In: Peters J-U, editor. Polypharmacology in Drug Discovery. Hoboken, New Jersey: John Wiley & Sons, Inc. 301-309.
16. Houghten RA, Pinilla C, Giulianotti MA, Appel JR, Dooley CT, et al. (2008) Strategies for the use of mixture-based synthetic combinatorial libraries: scaffold ranking, direct testing in vivo, and enhanced deconvolution by computational methods. J Comb Chem 10: 3-19.
17. Roberds SL, Filippov I, Alexandrov V, Hanania T, Brunner D, (2011) Rapid, computer vision-enabled murine screening system identifies neuropharmacological potential of two new mechanisms. Front Neurosci 5: 103.
18. Hanson JE, Orr AL, Fernandez-Illescas S, Valenzuela RA, Madison DV (2010) Hippocampal Slice Cultures. Protocols for Neural Cell Culture: Humana Press. 299-311.
19. Hanson JE, Deng L, Hackos DH, Lo SC, Lauffer BE, et al. (2013) Histone Deacetylase 2 Cell Autonomously Suppresses Excitatory and Enhances Inhibitory Synaptic Function in CA1 Pyramidal Neurons. J Neurosci 33: 5924-5929.
20. Comery TA, Martone RL, Aschmies S, Atchison KP, Diamantidis G, et al. (2005) Acute gamma-secretase inhibition improves contextual fear conditioning in the Tg2576 mouse model of Alzheimer's disease. J Neurosci 25: 8898-8902.
21. Alarcon JM, Malleret G, Touzani K, Vronskaya S, Ishii S, et al. (2004) Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 42: 947-959.
22. Levenson JM, O'Riordan KJ, Brown KD, Trinh MA, Molfese DL, et al. (2004) Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem 279: 40545-40559.
23. Vecsey CG, Hawk JD, Lattal KM, Stein JM, Fabian SA, et al. (2007) Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J Neurosci 27: 6128-6140.
24. Branco T, Staras K, (2009) The probability of neurotransmitter release: variability and feedback control at single synapses. Nat Rev Neurosci 10: 373-383.
25. Bliss TV, Collingridge GL, (1993) A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361: 31-39.
26. Martin SJ, Grimwood PD, Morris RG, (2000) Synaptic plasticity and memory: an evaluation of the hypothesis. Annu Rev Neurosci 23: 649-711.
27. Kim JJ, Fanselow MS, (1992) Modality-specific retrograde amnesia of fear. Science 256: 675-677.
28. Schenberg EE, Oliveira MG, (2008) Effects of pre or posttraining dorsal hippocampus D-AP5 injection on fear conditioning to tone, background, and foreground context. Hippocampus 18: 1089-1093.
29. Balducci C, Mehdawy B, Mare L, Giuliani A, Lorenzini L, et al. (2011) The gamma-secretase modulator CHF5074 restores memory and hippocampal synaptic plasticity in plaque-free Tg2576 mice. J Alzheimers Dis 24: 799-816.
30. Kilgore M, Miller CA, Fass DM, Hennig KM, Haggarty SJ, et al. (2010) Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 35: 870-880.
31. Ricobaraza A, Cuadrado-Tejedor M, Marco S, Perez-Otano I, Garcia-Osta A, (2012) Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus 22: 1040-1050.
32. Francis YI, Fa M, Ashraf H, Zhang H, Staniszewski A, et al. (2009) Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J Alzheimers Dis 18: 131-139.
33. Govindarajan N, Agis-Balboa RC, Walter J, Sananbenesi F, Fischer A, (2011) Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J Alzheimers Dis 26: 187-197.
34. Begley DJ, (2004) ABC transporters and the blood-brain barrier. Curr Pharm Des 10: 1295-1312.
35. Loscher W, Potschka H, (2005) Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2: 86-98.
36. Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, et al. (2003) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 100: 2041-2046.
37. Bradner JE, West N, Grachan ML, Greenberg EF, Haggarty SJ, et al. (2010) Chemical phylogenetics of histone deacetylases. Nat Chem Biol 6: 238-243.
38. Butler KV, Kozikowski AP, (2008) Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr Pharm Des 14: 505-528.
39. Tessier P, Smil DV, Wahhab A, Leit S, Rahil J, et al. (2009) Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. Bioorg Med Chem Lett 19: 5684-5688.
40. Beconi M, Aziz O, Matthews K, Moumne L, O'Connell C, et al. (2012) Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo. PLoS One 7: e44498.
41. Fass DM, Reis SA, Ghosh B, Hennig KM, Joseph NF, et al. (2013) Crebinostat: A novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity. Neuropharmacology.
42. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH, (2007) Recovery of learning and memory is associated with chromatin remodelling. Nature 447: 178-182.
43. Peleg S, Sananbenesi F, Zovoilis A, Burkhardt S, Bahari-Javan S, et al. (2010) Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 328: 753-756.
44. Spiller SE, Ditzler SH, Pullar BJ, Olson JM, (2008) Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J Neurooncol 87: 133-141.
45. Yin D, Ong JM, Hu J, Desmond JC, Kawamata N, et al. (2007) Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res 13: 1045-1052.
46. Lee J, Lund-Smith C, Borboa A, Gonzalez AM, Baird A, et al. (2009) Glioma-induced remodeling of the neurovascular unit. Brain Res 1288: 125-134.
47. Lund CV, Nguyen MT, Owens GC, Pakchoian AJ, Shaterian A, et al. (2006) Reduced glioma infiltration in Src-deficient mice. J Neurooncol 78: 19-29.
48. Liner KJ, 2nd, Ro MJ, Robertson KR (2010) HIV, antiretroviral therapies, and the brain. Curr HIV/AIDS Rep 7: 85-91.
49. Thompson KA, Cherry CL, Bell JE, McLean CA, (2011) Brain cell reservoirs of latent virus in presymptomatic HIV-infected individuals. Am J Pathol 179: 1623-1629.